• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

全长和裂解形式的尿激酶型纤溶酶原激活物可溶性受体在卵巢癌囊液中高浓度存在。

Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer.

作者信息

Wahlberg K, Høyer-Hansen G, Casslén B

机构信息

Department of Obstetrics and Gynecology, University Hospital, Lund, Sweden.

出版信息

Cancer Res. 1998 Aug 1;58(15):3294-8.

PMID:9699658
Abstract

We assayed the levels of soluble urokinase plasminogen activator receptor (su-PAR) with an ELISA in various body fluids from 77 patients with benign or malignant ovarian tumors, histologically classified as follows: benign; possibly malignant (borderline); and well, intermediately, and poorly differentiated malignant. The concentration of su-PAR in fluid from malignant cysts was extremely high, approximately 10-fold higher than the concentration in ascitic fluid and approximately 100-fold higher than that in blood. Also, the concentration in malignant cysts was approximately 10-fold higher than the concentration in benign cysts. Such high concentrations of su-PAR were found not only in truly malignant but also in possibly malignant cysts. Thus, we suggest that the concentration of su-PAR in cystic fluid can serve as a marker, allowing early diagnosis of malignant ovarian cysts. The concentration of su-PAR in fluid aspirated transvaginally with ultrasonographic guidance can be used to discriminate possibly and truly malignant cysts from benign cysts without surgery. The high concentrations of su-PAR in ovarian cystic fluids allowed us to characterize the molecular forms. Cross-linking of a radiolabeled ligand to the receptor demonstrated that at least a fraction of su-PAR was able to bind the ligand. A cleaved form of the receptor constituting domains 2 and 3 was detected with Western blotting. The cleaved receptor, which is devoid of the ligand-binding domain 1, has not previously been demonstrated in body fluids; it has only been demonstrated on cell surfaces. su-PAR domains 2 and 3 were found in cystic fluids from both malignant and benign ovarian tumors.

摘要

我们采用酶联免疫吸附测定法(ELISA)检测了77例良性或恶性卵巢肿瘤患者各种体液中可溶性尿激酶型纤溶酶原激活物受体(su-PAR)的水平,这些肿瘤在组织学上分类如下:良性;可能恶性(交界性);以及高分化、中分化和低分化恶性肿瘤。恶性囊肿液中su-PAR的浓度极高,比腹水浓度高约10倍,比血液浓度高约100倍。此外,恶性囊肿中的浓度比良性囊肿中的浓度高约10倍。不仅在真正的恶性囊肿中,而且在可能恶性的囊肿中都发现了如此高浓度的su-PAR。因此,我们认为囊肿液中su-PAR的浓度可作为一种标志物,有助于早期诊断恶性卵巢囊肿。在超声引导下经阴道抽吸的液体中su-PAR的浓度可用于在不进行手术的情况下区分可能的和真正的恶性囊肿与良性囊肿。卵巢囊肿液中高浓度的su-PAR使我们能够对其分子形式进行表征。放射性标记配体与受体的交联表明,至少一部分su-PAR能够结合该配体。通过蛋白质印迹法检测到了由结构域2和3组成的受体裂解形式。这种缺乏配体结合结构域1的裂解受体此前尚未在体液中得到证实;仅在细胞表面得到证实。在恶性和良性卵巢肿瘤的囊肿液中均发现了su-PAR结构域2和3。

相似文献

1
Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer.全长和裂解形式的尿激酶型纤溶酶原激活物可溶性受体在卵巢癌囊液中高浓度存在。
Cancer Res. 1998 Aug 1;58(15):3294-8.
2
A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.卵巢癌患者腹水中存在一种无配体的可溶性尿激酶受体。
J Clin Invest. 1993 Nov;92(5):2160-7. doi: 10.1172/JCI116817.
3
Higher levels of soluble E-cadherin in cyst fluid from malignant ovarian tumours than in benign cysts.恶性卵巢肿瘤囊液中可溶性E-钙黏蛋白水平高于良性囊肿。
Anticancer Res. 2001 Jan-Feb;21(1A):65-70.
4
Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer.血浆中尿激酶型纤溶酶原激活物受体的裂解形式具有诊断潜力,并可预测卵巢癌患者的术后生存率。
Clin Cancer Res. 2008 Sep 15;14(18):5785-93. doi: 10.1158/1078-0432.CCR-08-0096.
5
Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.妇科癌症或良性妇科疾病患者术前采集血浆中的可溶性尿激酶型纤溶酶原激活物受体
Gynecol Oncol. 2001 Sep;82(3):523-31. doi: 10.1006/gyno.2001.6324.
6
The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients.卵巢癌患者血清中尿激酶型纤溶酶原激活物受体水平升高。
Cancer Res. 1998 May 1;58(9):1843-9.
7
Calgranulins in cystic fluid and serum from patients with ovarian carcinomas.卵巢癌患者囊液和血清中的钙粒蛋白
Cancer Res. 2003 Nov 1;63(21):7507-14.
8
Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy.卵巢囊肿液中血管内皮生长因子水平与恶性肿瘤相关。
Clin Cancer Res. 1999 Apr;5(4):823-9.
9
The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.血浆可溶性尿激酶型纤溶酶原激活物受体(suPAR)水平在Ⅲ期卵巢癌患者中的预后价值。
Anticancer Res. 2004 May-Jun;24(3b):1981-5.
10
Vascular endothelial growth factor and its soluble receptor in benign and malignant ovarian tumors.血管内皮生长因子及其可溶性受体在卵巢良恶性肿瘤中的表达
Biomed Pharmacother. 2008 Jul-Aug;62(6):373-7. doi: 10.1016/j.biopha.2007.10.005. Epub 2007 Oct 30.

引用本文的文献

1
COVID-19 Biomarkers in research: Extension of the OncoMX cancer biomarker data model to capture biomarker data from other diseases.研究中的新冠病毒生物标志物:扩展OncoMX癌症生物标志物数据模型以获取其他疾病的生物标志物数据。
bioRxiv. 2020 Sep 10:2020.09.09.196220. doi: 10.1101/2020.09.09.196220.
2
Relating GPI-Anchored Ly6 Proteins uPAR and CD59 to Viral Infection.将 GPI 锚定的 Ly6 蛋白 uPAR 和 CD59 与病毒感染联系起来。
Viruses. 2019 Nov 14;11(11):1060. doi: 10.3390/v11111060.
3
Soluble Urokinase Receptor and the Kidney Response in Diabetes Mellitus.
可溶性尿激酶受体与糖尿病中的肾脏反应
J Diabetes Res. 2017;2017:3232848. doi: 10.1155/2017/3232848. Epub 2017 May 17.
4
Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor - β1 (TGF-β1) and potential effects on migration and invasion.口腔癌细胞上尿激酶受体(uPAR)的裂解:转化生长因子-β1(TGF-β1)的调节作用及其对迁移和侵袭的潜在影响
BMC Cancer. 2017 May 19;17(1):350. doi: 10.1186/s12885-017-3349-7.
5
The Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Acute Myeloid Leukemia.可溶性尿激酶型纤溶酶原激活物受体在急性髓系白血病中的预后意义
Turk J Haematol. 2016 Jun 5;33(2):135-40. doi: 10.4274/tjh.2014.0405. Epub 2015 Aug 6.
6
Tumour microenvironments induce expression of urokinase plasminogen activator receptor (uPAR) and concomitant activation of gelatinolytic enzymes.肿瘤微环境诱导尿激酶型纤溶酶原激活物受体(uPAR)的表达并伴随明胶酶的激活。
PLoS One. 2014 Aug 26;9(8):e105929. doi: 10.1371/journal.pone.0105929. eCollection 2014.
7
Role of urokinase receptor in tumor progression and development.尿激酶受体在肿瘤演进和发展中的作用。
Theranostics. 2013 Jun 25;3(7):487-95. doi: 10.7150/thno.4218. Print 2013.
8
Ovarian cyst fluid is a rich proteome resource for detection of new tumor biomarkers.卵巢囊液是一种富含蛋白质组的资源,可用于检测新的肿瘤生物标志物。
Clin Proteomics. 2012 Dec 27;9(1):14. doi: 10.1186/1559-0275-9-14.
9
Detection of suPAR in the Saliva of Healthy Young Adults: Comparison with Plasma Levels.健康年轻成年人唾液中可溶性尿激酶型纤溶酶原激活物受体(suPAR)的检测:与血浆水平的比较
Biomark Insights. 2011;6:119-25. doi: 10.4137/BMI.S8326. Epub 2011 Oct 25.
10
Regulation of cell signalling by uPAR.尿激酶型纤溶酶原激活物受体(uPAR)对细胞信号的调节。
Nat Rev Mol Cell Biol. 2010 Jan;11(1):23-36. doi: 10.1038/nrm2821.